Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Poland / NCT06821906
Recruiting Phase 2

Stereotactic Radiosurgery in the Treatment of Essential Tremor

NCT06821906 · tracked via the Priya Life Science Poland tracker
Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Phase
Phase 2
Started
2024-12-16
Last updated
2025-02-12

Condition(s) studied

Essential Tremor

Investigational drug(s) / intervention(s)

Stereotactic RadiosurgeryStereotactic Radiosurgery

Stereotactic Radiosurgery: Frameless Stereotactic Radiosurgery- CyberKnife with a dose of 80 Gy

Stereotactic Radiosurgery: Frameless Stereotactic Radiosurgery- CyberKnife with a dose of 130 Gy

Study summary

The goal of this interventional study is to evaluate the effectiveness of treatment using stereotactic radiosurgery in the treatment of essential tremor in adult patients

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Essential tremor diagnosed, Parkinson's disease and other causes of tremor excluded. * Insufficient tremor control despite the use of available pharmacotherapy methods. * Disqualification from the Deeply Brain Stimualtion procedure/lack of consent to perform it on the side qualified for Stereotactic Radiosurgery * Consent to participate in a clinical trial. Exclusion Criteria: * Age under 50 * Pregnancy * Duration of the disease less than 5 years * Dementia, psychosis or other condition that prevents giving informed consent to participate in the study * Poor general condition, serious comorbidities * Structural changes in the basal ganglia or major atrophic changes * Previous radiotherapy to the brain covering the potential treatment area * Medical contraindications to magnetic resonance imaging

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch Gliwice Poland Recruiting

More Maria Sklodowska-Curie National Research Institute of Oncology trials in Poland

Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial Active, not recruiting
Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer Recruiting
Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines Active, not recruiting
Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy Recruiting
NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06821906 on ClinicalTrials.gov ↗ ← All trials in Poland